ArticleOphthalmology and therapy2023
Challenging the "Topical Medications-First" Approach to Glaucoma: A Treatment Paradigm in Evolution.
Article in Ophthalmology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- The effect of selective laser trabeculoplasty on the intraocular pressure of the contralateral eye - a systematic review and meta-analysis.Eye (London, England) · 2026Pooled it
- Comparison of existing polypharmacy measures to a measure incorporating all modes of administration: an observational study using routinely collected data.International journal of clinical pharmacy · 2026Observational
- TeleGlaukos: A Clinician-Led Adaptive Telemonitoring Platform for Hybrid Glaucoma Care.Bioengineering (Basel, Switzerland) · 2026Article
- Risk-Stratified Interventional Management and Surgical Decision-Making in Primary Glaucoma.Biomedicines · 2026Review
- A Multimodal Approach to Open-Angle Glaucoma with Travoprost Intracameral Implant and Minimally Invasive Glaucoma Surgery with or Without Concurrent Cataract Surgery.Ophthalmology and therapy · 2026Article
- Clinical recommendations for early identification of patients with open-angle glaucoma at higher risk of low adherence to topical treatment: An Italian Delphi consensus.Acta ophthalmologica · 2026Article
- Prospective Pilot Study of Sustained Release Bimatoprost Implant with SpyGlass Intraocular Lens: 3-Year Results.Ophthalmology and therapy · 2026Article
- The Future of Interventional Keratoconus Management: Perspectives on Integrating Epithelium-on Oxygen-Enriched Cross-Linking into Comprehensive Care Pathways.Therapeutics and clinical risk management · 2026Article
- Assessment of the Effectiveness, Tolerability, and Safety of the Preservative-Free Fixed Combination of Timolol, Dorzolamide, and Brimonidine Compared to Separate Therapies in Patients with Glaucoma, a Randomized Controlled Trial.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Ocular Surface Changes and Glaucoma: A Prospective Contralateral Study of IOP-Reducing Eyedrops versus iStent Inject Surgery.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Administration of the Travoprost Intracameral Implant in an Office-Based Surgery Setting.Ophthalmology and therapy · 2025Article
- Clinical Benefits of Preservative-Free Treatment for Glaucoma with a Focus on Preservative-Free Latanoprost.Ophthalmology and therapy · 2025Review
- Non-Contact Laser Therapy for Glaucoma: A Review of Direct Selective Laser Trabeculoplasty.Journal of clinical medicine · 2025Review
- Third-Generation Trabecular Micro-Bypass Implantation and Phacoemulsification in Patients with Glaucoma: A Multicenter Study.Vision (Basel, Switzerland) · 2025Article
- A quantum-inspired neural fuzzy sliding mode control framework for fractional-order modeling of intraocular pressure regulation and optic nerve damage in glaucoma.Scientific reports · 2025Article
- Five-Year Outcomes of iStent inject Implantation With or Without Phacoemulsification in Eyes with Open-Angle Glaucoma.Ophthalmology and therapy · 2025Article
- Aqueous Humor Concentrations of Travoprost Free Acid and Residual Drug in Explanted Implants from Patients Administered a Travoprost Intracameral Implant.Ophthalmology and therapy · 2025Article
- Six-Month Outcomes from a Prospective, Randomized Study of iStent infinite Versus Hydrus in Open-Angle Glaucoma: The INTEGRITY Study.Ophthalmology and therapy · 2025Article
- Third-Generation Trabecular Micro-Bypass Implantation with Phacoemulsification for Glaucoma.Ophthalmology and therapy · 2025Article
- Travoprost Intracameral Implant in Eyes with Glaucoma or Ocular Hypertension: Early Short-Term Real-World Outcomes.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topical glaucoma medications are effective and safe, but they have numerous well-documented limitations that diminish their long-term utility and sustainability. These limitations can include high rates of nonadherence (with associated glaucoma progression), concerning side effects, inconsistent circadian intraocular pressure (IOP) control, complex dosing regimens, difficulty with self-administration, costs, and decreased quality of life. Despite these limitations, topical medications traditionally have been first-line in the glaucoma treatment algorithm, as no other minimally invasive treatment alternatives existed. In recent years, however, novel interventional therapies-including sustained-release drug-delivery platforms, selective laser trabeculoplasty, and micro-invasive glaucoma surgery procedures-have made it possible to intervene earlier without relying on topical medications. As a result, the topical medication-first treatment approach is being reevaluated in an overall shift toward earlier more proactive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.